// peepdf comment: Javascript code located in object 42 (version 1)

0 G
0 J 0 j 2.2 w 10 M[] 0 d / GS1 gs
1 i
45 744 m
567 744 l
S
0.3 w
45 740 m
567 740 l
S
BT / F1 1 Tf
11 0 0 11 45 750 Tm
0 g
0 Tc(72090) Tj
9.8 0 0 10 130.2 750 Tm
0.227 Tw(Federal Register) Tj / F2 1 Tf
8.0007 0 TD[(/)-165(Vol. 64, No. 246)-165(/) - 165(Thursday, December 23, 1999) - 165(/)-165(Notices)]TJ
9 0 0 9 54 725 Tm
-0.004 Tw
(The meeting is closed to the public.)Tj
8 0 0 8 53 712.4 Tm
-0.003 Tw
(Dated: December 16, 1999.)Tj
/F1
1 Tf - 1 - 1.325 TD(LaVerne Y.Stringfield, ) Tj / F3 1 Tf
T * -0.058 Tw(Director, Office of Federal Advisory) Tj
0 - 1.1125 TD(Committee Policy.) Tj / F2 1 Tf
0 - 1.3875 TD - 0.003 Tw([FR Doc.99\26133295 Filed 12\26122\26199; 8: 45 am]) Tj / F - 6 1 Tf
6 0 0 6 45 660.6 Tm
0.163 Tw(BILLING CODE 4140\26101\261M) Tj
ET
45 650.34 m
213 650.34 l
S
BT
9 0 0 9 45 632.6 Tm - 0.004 Tw(DEPARTMENT OF HEALTH AND) Tj
0 - 1.1 TD(HUMAN SERVICES) Tj
0 - 1.9556 TD
0.051 Tw(National Institutes of Health) Tj
0 - 1.9667 TD - 0.004 Tw(Principles and Guidelines
for) Tj
0 - 1.1 TD(Recipients of NIH Research Grants and) Tj
T * (Contracts on Obtaining and) Tj
T * (Disseminating Biomedical Research) Tj
T * (Resources: Final Notice) Tj
7.2 0 0 7.441 45 533.4 Tm(AGENCY) Tj
9 0 0 9 75.8 533.4 Tm(: ) Tj / F2 1 Tf

// peepdf comment: Javascript code located in object 6 (version 1)

0 G
0 J 0 j 2.2 w 10 M[] 0 d / GS1 gs
1 i
45 744 m
567 744 l
S
0.3 w
45 740 m
567 740 l
S
BT / F1 1 Tf
11 0 0 11 45 750 Tm
0 g
0 Tc(72092) Tj
9.8 0 0 10 130.2 750 Tm
0.227 Tw(Federal Register) Tj / F2 1 Tf
8.0007 0 TD[(/)-165(Vol. 64, No. 246)-165(/) - 165(Thursday, December 23, 1999) - 165(/)-165(Notices)]TJ
ET
0.5 w 
222 189.8 m
272 189.8 l
S
BT
5.446 0 0 4.55 229 182.909 Tm
0 Tw
(1)Tj
7 0 0 7 233.168 181.1 Tm
-0.003 Tw
(The term ``unique research resource'' is used in)Tj
-1.5954 -1.1429 TD
(its broadest sense to embrace the full range of tools)Tj
T*
(that scientists use in the laboratory, including cell)Tj
T*
(lines, monoclonal antibodies, reagents, animal)Tj
T*
(models, growth factors, combinatorial chemistry)Tj
T*
(and DNA libraries, clones and cloning tools \(such)Tj
T*
(as PCR\), methods, laboratory equipment and)Tj
T*
(machines. The terms ``research tools'' and)Tj
T*
(``materials'' are used throughout this document)Tj
T*
(interchangeably with ``unique research resources.'')Tj
T*
(Databases and materials subject to copyright, such)Tj
T*
(as software, are also research tools in many)Tj
T*
(contexts. Although the information provided here)Tj
T*
(may be applicable to such resources, the NIH)Tj
T*
(recognizes that databases and software present)Tj
T*
(unique questions which cannot be fully explored in)Tj
T*
(this document.)Tj
9 0 0 9 54 725 Tm
-0.004 Tw
(Several commenters suggested that)Tj
-1 -1.1111 TD
(research tools be better defined and that)Tj
T*
(more examples be used to assist in)Tj
T*
(determining whether the policy should)Tj
T*
(be applied and if so, what licensing)Tj
T*
(strategy is appropriate. For example,)Tj
T*
(one commenter suggested that the)Tj
T*
(policy draw a distinction between)Tj
T*
(``broad platform technologies'' and)Tj
T*
(``product-specific technologies'' when)Tj
T*
(determining whether an exclusive)Tj
T*
(license is appropriate. The final policy)Tj
T*
(provides clarification of the criteria that)Tj
T*
(Recipients might apply in determining)Tj
T*
(how to handle a particular technology.)Tj
1 -1.1111 TD
(One commenter requested that the)Tj
-1 -1.1111 TD
(definition of research tools be expanded)Tj
T*
(to include diagnostic genetic tests)Tj
T*
(performed with ``home-brew'' reagents.)Tj
T*
(The commenter suggested that the)Tj
T*
(patenting and exclusive licensing of)Tj
T*
(such tests is having a deleterious effect)Tj
T*
(on clinical education, clinical research,)Tj
T*
(and patient care. NIH declines to)Tj
T*
(expand the definition of research tools)Tj
T*
(to include diagnostic genetic tests.)Tj
T*
(Where such tests are patented and)Tj
T*
(licensed to for-profit entities, academic)Tj
T*
(medical centers wishing to use such)Tj
T*
(licensed tests in their clinical programs)Tj
T*
(should negotiate terms of use with the)Tj
T*
(commercial licensee.)Tj
1 -1.1111 TD
(Many commenters were of the)Tj
-1 -1.1111 TD
(opinion that the thirty-day time limit for)Tj
T*
(disclosure of research findings was too)Tj
T*
(short. The final policy has been)Tj
T*
(amended to state that a delay of 30\26160)Tj
T*
(days is generally viewed as reasonable.)Tj
T*
(This amendment is in accord with)Tj
T*
(previous NIH guidance on sponsored)Tj
T*
(research agreements, Developing)Tj
T*
(Sponsored Research Agreements:)Tj
T*
(Considerations for Recipients of NIH)Tj
T*
(Research Grants and Contracts, 59 FR)Tj
T*
(55674.)Tj
1 -1.1111 TD
(Comments were received in favor of)Tj
-1 -1.1111 TD
(adopting the Simple Letter Agreement)Tj
T*
(as a free-standing, one page, uniform)Tj
T*
(material transfer agreement. If used by)Tj
T*
(the NIH intramural program and NIH)Tj
T*
(grantees, commenters believe that the)Tj
T*
(majority of transfers among and between)Tj
T*
(not-for-profits and government)Tj
T*
(laboratories would be greatly simplified.)Tj
T*
(In response to specific comments, the)Tj
T*
(Simple Letter Agreement has been)Tj
T*
(significantly edited and updated.)Tj
T*
(Recipients are encouraged to adopt the)Tj
T*
(Simple Letter Agreement as their)Tj
T*
(institution's model Material Transfer)Tj
T*
(Agreement \(MTA\), and are expected to)Tj
T*
(use the terms of the Simple Letter)Tj
T*
(Agreement, or no more restrictive terms,)Tj
T*
(for transfers of unpatented materials)Tj
T*
(developed with NIH funding to other)Tj
T*
(NIH grantees.)Tj
/F - 6 1 Tf
7.2 0 0 7.441 45 63 Tm[(FOR) - 342(FURTHER) - 342(INFORMATION) - 342(CONTACT)] TJ
9 0 0 9 187.958 63 Tm(: ) Tj / F2 1 Tf
0.6065 0 TD(Ms.) Tj - 16.4907 - 1.1111 TD(Barbara McGarey, J.D., NIH Office of) Tj
19.6667 74.6666 TD(Technology Transfer, 6011 Executive) Tj
0 - 1.1 TD(Boulevard, Suite 325, Rockville, MD) Tj
T * (20852\2613804; Fax: \ (301\) 402\2613257;
E - ) Tj
T * (mail: NIHOTT@od.nih.gov.) Tj
8 0 0 8 230 682.5 Tm - 0.003 Tw(Dated: December 14,
1999.) Tj / F1 1 Tf - 1 - 1.35 TD(Maria C.Freire, ) Tj / F3 1 Tf
T * -0.058 Tw(Director, Office of Technology Transfer, ) Tj
0 - 1.1125 TD(National Institutes of Health.) Tj / F1 1 Tf
9 0 0 9 222 637.2 Tm - 0.004 Tw(Sharing Biomedical Research) Tj
0 - 1.1 TD(Resources: Principles and Guidelines) Tj
T * (
for Recipients of NIH Research Grants) Tj
T * (and Contracts) Tj
0 - 1.5333 TD(Introduction) Tj / F2 1 Tf
1 - 1.4667 TD(The National Institutes of Health is) Tj - 1 - 1.1111 TD(dedicated to the advancement of health) Tj
T * (through science.As a public sponsor of) Tj
T * (biomedical research, NIH has a dual) Tj
T * (interest in accelerating scientific) Tj
T * (discovery and facilitating product) Tj
T * (development.In 1997, Dr.Harold) Tj
T * (Varmus, Director, NIH requested that a) Tj
T * (Working Group of the Advisory) Tj
T * (Committee to the Director look into) Tj
T * (problems encountered in the) Tj
T * (dissemination and use of unique) Tj
T * (research resources, the competing) Tj
T * (interests of intellectual property owners) Tj
T * (and research tool users, and possible) Tj
T * (NIH responses.) Tj
7.002 0 0 5.85 284.453 432.828 Tm
0 Tw(1) Tj
9 0 0 9 290.807 430.5 Tm - 0.004 Tw(The Working Group) Tj - 7.6452 - 1.1111 TD(found that intellectual property) Tj
T * (restrictions can stifle the broad) Tj
T * (dissemination of new discoveries and) Tj
T * (limit future avenues of research and) Tj
T * (product development.At the same time, ) Tj
T * (reasonable restrictions on the) Tj
T * (dissemination of research tools are) Tj
T * (sometimes necessary to protect) Tj
T * (legitimate proprietary interests and to) Tj
T * (preserve incentives
for commercial) Tj
T * (development.One of the) Tj
T * (recommendations of the Working Group) Tj
T * (was that NIH issue guidance to its) Tj
T * (funding recipients to help them achieve) Tj
T * (the appropriate balance.That guidance) Tj
T * (is provided in this two - part document, ) Tj
T * (consisting of Principles setting forth the) Tj
T * (fundamental concepts and Guidelines) Tj
T * (that provide specific information to) Tj
T * (patent and license professionals and) Tj
T * (sponsored research administrators
for) Tj
T * (implementation.A copy of the full) Tj
T * (Report of the Working Group, with more) Tj
19.6667 58.2778 TD(detailed background information, is) Tj
0 - 1.1111 TD(available at the NIH web site, ) Tj
T * (www.nih.gov / welcome / forum, or from) Tj
T * (the NIH Office of the Director.) Tj / F1 1 Tf
0 - 1.6667 TD(Principles) Tj / F3 1 Tf
T * (1.Ensure Academic Freedom and) Tj
0 - 1.1111 TD(Publication) Tj / F2 1 Tf
1 - 1.5222 TD(Academic research freedom based) Tj - 1 - 1.1111 TD(upon collaboration, and the scrutiny of) Tj
T * (research findings within the scientific) Tj
T * (community, are at the heart of the) Tj
T * (scientific enterprise.Institutions that) Tj
T * (receive NIH research funding through) Tj
T * (grants, cooperative agreements or) Tj
T * (contracts\ (``Recipients ''\) have an) Tj
T * (obligation to preserve research freedom, ) Tj
T * (safeguard appropriate authorship, and) Tj
T * (ensure timely disclosure of their) Tj
T * (scientists ' research findings through, for)Tj
T*
(example, publications and presentations)Tj
T*
(at scientific meetings. Recipients are)Tj
T*
(expected to avoid signing agreements)Tj
T*
(that unduly limit the freedom of)Tj
T*
(investigators to collaborate and publish,)Tj
T*
(or that automatically grant co-)Tj
T*
(authorship or copyright to the provider)Tj
T*
(of a material.)Tj
1 -1.0778 TD
(Reasonable restrictions on)Tj
-1 -1.1111 TD
(collaboration by academic researchers)Tj
T*
(involved in sponsored research)Tj
T*
(agreements with an industrial partner)Tj
T*
(that avoid conflicting obligations to)Tj
T*
(other industrial partners, are understood)Tj
T*
(and accepted. Similarly, brief delays in)Tj
T*
(publication may be appropriate to)Tj
T*
(permit the filing of patent applications)Tj
T*
(and to ensure that confidential)Tj
T*
(information obtained from a sponsor or)Tj
T*
(the provider of a research tool is not)Tj
T*
(inadvertently disclosed. However,)Tj
T*
(excessive publication delays or)Tj
T*
(requirements for editorial control,)Tj
T*
(approval of publications, or withholding)Tj
T*
(of data all undermine the credibility of)Tj
T*
(research results and are unacceptable.)Tj
/F3 1 Tf
0 -1.6667 TD
(2. Ensure Appropriate Implementation)Tj
0 -1.1111 TD
(of the Bayh-Dole Act)Tj
/F2 1 Tf
1 -1.5333 TD
(When a Recipient'
s research work is) Tj - 1 - 1.1111 TD(funded by NIH, the activity is subject to) Tj
T * (various laws and regulations, including) Tj
T * (the Bayh - Dole Act\ (35 U.S.C.200) Tj / F3 1 Tf
15.4767 0 TD(et) Tj - 15.4767 - 1.1111 TD(seq.) Tj / F2 1 Tf
1.7779 0 TD(\).Generally, Recipients are expected) Tj - 1.7779 - 1.1111 TD(to maximize the use of their research) Tj
T * (findings by making them available to) Tj
T * (the research community and the public, ) Tj
T * (and through their timely transfer to) Tj
T * (industry
for commercialization.) Tj
1 - 1.0889 TD(The right of Recipients to retain title) Tj - 1 - 1.1111 TD(to inventions made with NIH funds) Tj
T * (comes with the corresponding) Tj
T * (obligations to promote utilization, ) Tj
T * (commercialization, and public) Tj
T * (availability of these inventions.The) Tj
T * (Bayh - Dole Act encourages Recipients to) Tj
T * (patent and license subject inventions as) Tj
T * (one means of fulfilling these obligations.) Tj / F - 5 1 Tf
6.5 0 0 6.5 60 20 Tm
1 g
0 Tw[(VerDate 10 - DEC - 99) - 1077(10: 32 Dec 22,
1999) - 1077(Jkt 190000) - 1077(PO 00000) - 1077(Frm 00030) - 1077(Fmt 4703) - 1077(Sfmt 4703) - 1077(E: \\FR\\FM\\A23DE3.092) - 1077(pfrm07) - 1077(PsN: 23DEN1)] TJ
ET

// peepdf comment: Javascript code located in object 12 (version 1)

0 G
0 J 0 j 2.2 w 10 M[] 0 d / GS1 gs
1 i
45 744 m
567 744 l
S
0.3 w
45 740 m
567 740 l
S
BT / F1 1 Tf
11 0 0 11 45 750 Tm
0 g
0 Tc(72094) Tj
9.8 0 0 10 130.2 750 Tm
0.227 Tw(Federal Register) Tj / F2 1 Tf
8.0007 0 TD[(/)-165(Vol. 64, No. 246)-165(/) - 165(Thursday, December 23, 1999) - 165(/)-165(Notices)]TJ
/F1
1 Tf
9 0 0 9 45 725 Tm - 0.004 Tw(Guidelines
for Disseminating Research) Tj
0 - 1.1 TD(Resources Arising Out of NIH - Funded) Tj
T * (Research) Tj / F3 1 Tf
0 - 1.6444 TD(Definition of Research Tools) Tj / F2 1 Tf
1 - 1.4667 TD(The definition of research tools is) Tj - 1 - 1.1 TD(necessarily broad, and it is) Tj
T * (acknowledged that the same material) Tj
T * (can have different uses, being a research) Tj
T * (tool in some contexts and a product in ) Tj
T * (others.In determining how an NIH - ) Tj
T * (funded resource that falls within the) Tj
T * (definition should be handled, ) Tj
T * (Recipients should determine whether: ) Tj
T * (\ (1\) The Primary usefulness of the) Tj
T * (resource is as a tool
for discovery rather) Tj
T * (than an FDA - approved product or) Tj
T * (integral component of such a product;) Tj
T * (\ (2\) the resource is a broad, enabling) Tj
T * (invention that will be useful to many) Tj
T * (scientists\ (or multiple companies in ) Tj
T * (developing multiple products\), rather) Tj
T * (than a project or product - specific) Tj
T * (resource; and\ (3\) the resource is readily) Tj
T * (useable or distributable as a tool rather) Tj
T * (than the situation where private sector) Tj
T * (involvement is necessary or the most) Tj
T * (expedient means
for developing or) Tj
T * (distributing the resource.Recipients) Tj
T * (should ensure that their intellectual) Tj
T * (property strategy
for resources fitting) Tj
T * (one or more of the above criteria) Tj
T * (enhances rather than restricts the) Tj
T * (ultimate availability of the resource.If) Tj
T * (Recipient believes private sector) Tj
T * (involvement is desirable to achieve this) Tj
0 - 1.1111 TD(goal, Recipient should strategically) Tj
T * (license the invention under terms) Tj
T * (commensurate with the goal.) Tj / F3 1 Tf
0 - 1.6444 TD(Use of Simple Letter Agreement) Tj / F2 1 Tf
1 - 1.4667 TD(Recipients are expected to ensure that) Tj - 1 - 1.1111 TD(unique research resources arising from) Tj
T * (NIH - funded research are made available) Tj
T * (to the scientific research community.) Tj
T * (The majority of transfers to not -
for -) Tj
T * (profit entities should be implemented) Tj
T * (under terms no more restrictive than the) Tj
T * (UBMTA.In particular, Recipients are) Tj
T * (expected to use the Simple Letter) Tj
T * (Agreement provided below, or another) Tj
T * (document with no more restrictive) Tj
T * (terms, to readily transfer unpatented) Tj
T * (tools developed with NIH funds to other) Tj
T * (Recipients
for use in NIH - funded) Tj
T * (projects.If the materials are patented or) Tj
T * (licensed to an exclusive provider, other) Tj
T * (arrangements may be used, but) Tj
T * (commercialization option rights, royalty) Tj
T * (reach - through, or product reach - through) Tj
T * (rights back to the provider are) Tj
T * (inappropriate.) Tj
1 - 1.0222 TD(Similarly, when
for -profit entities are) Tj - 1 - 1.1111 TD(seeking access to NIH - funded tools
for) Tj
T * (internal use purposes, Recipients) Tj
T * (should ensure that the tools are) Tj
T * (transferred with the fewest) Tj
T * (encumbrances possible.The Simple) Tj
T * (Letter Agreement may be expanded
for) Tj
19.6667 74.6667 TD(use in transferring tools to
for -profit) Tj
0 - 1.1111 TD(entities, or simple internal use license) Tj
T * (agreements with execution or annual) Tj
T * (use fees may be appropriate.) Tj
0 - 1.6667 TD(Simple Letter Agreement
for the) Tj
0 - 1.1111 TD(Transfer of Materials) Tj
1 - 1.4667 TD(In response to RECIPIENT 's request)Tj
-1 -1.1111 TD
(for the MATERIAL [insert description])Tj
/T-1 1 Tf
T*
(lllll )Tj
/F2 1 Tf
5.3024 0 TD
(the PROVIDER asks that the)Tj
-5.3024 -1.1111 TD
(RECIPIENT and the RECIPIENT)Tj
T*
(SCIENTIST agree to the following before)Tj
T*
(the RECIPIENT receives the MATERIAL:)Tj
1 -1.0222 TD
(1. The above MATERIAL is the)Tj
-1 -1.1111 TD
(property of the PROVIDER and is made)Tj
T*
(available as a service to the research)Tj
T*
(community.)Tj
1 -1.0222 TD
(2. THIS MATERIAL IS NOT FOR USE)Tj
-1 -1.1111 TD
(IN HUMAN SUBJECTS.)Tj
1 -1.0222 TD
(3. The MATERIAL will be used for)Tj
-1 -1.1111 TD
(teaching or not-for-profit research)Tj
T*
(purposes only.)Tj
1 -1.0222 TD
(4. The MATERIAL will not be further)Tj
-1 -1.1111 TD
(distributed to others without the)Tj
T*
(PROVIDER'
s written consent.The) Tj
T * (RECIPIENT shall refer any request
for) Tj
T * (the MATERIAL to the PROVIDER.To) Tj
T * (the extent supplies are available, the) Tj
T * (PROVIDER or the PROVIDER) Tj
T * (SCIENTIST agree to make the) Tj
T * (MATERIAL available, under a separate) Tj
T * (Simple Letter Agreement to other) Tj
T * (scientists
for teaching or not -
for -profit) Tj
T * (research purposes only.) Tj
1 - 1.0222 TD(5.The RECIPIENT agrees to) Tj - 1 - 1.1111 TD(acknowledge the source of the) Tj
T * (MATERIAL in any publications) Tj
T * (reporting use of it.) Tj
1 - 1.0222 TD(6.Any MATERIAL delivered) Tj - 1 - 1.1111 TD(pursuant to this Agreement is) Tj
T * (understood to be experimental in nature) Tj
T * (and may have hazardous properties.) Tj
T * (THE PROVIDER MAKES NO) Tj
T * (REPRESENTATIONS AND EXTENDS) Tj
T * (NO WARRANTIES OF ANY KIND, ) Tj
T * (EITHER EXPRESSED OR IMPLIED.) Tj
T * (THERE ARE NO EXPRESS OR IMPLIED) Tj
T * (WARRANTIES OF) Tj
T * (MERCHANTABILITY OR FITNESS FOR) Tj
T * (A PARTICULAR PURPOSE, OR THAT) Tj
T * (THE USE OF THE MATERIAL WILL) Tj
T * (NOT INFRINGE ANY PATENT, ) Tj
T * (COPYRIGHT, TRADEMARK, OR) Tj
T * (OTHER PROPRIETARY RIGHTS.Unless) Tj
T * (prohibited by law, Recipient assumes all) Tj
T * (liability
for claims
for damages against) Tj
T * (it by third parties which may arise from) Tj
T * (the use, storage or disposal of the) Tj
T * (Material except that, to the extent) Tj
T * (permitted by law, the Provider shall be) Tj
T * (liable to the Recipient when the damage) Tj
T * (is caused by the gross negligence or) Tj
T * (willful misconduct of the Provider.) Tj
1 - 1.0333 TD(7.The RECIPIENT agrees to use the) Tj - 1 - 1.1111 TD(MATERIAL in compliance with all) Tj
T * (applicable statutes and regulations.) Tj
1 - 1.0333 TD(8.The MATERIAL is provided at no) Tj - 1 - 1.1111 TD(cost, or with an optional transmittal fee) Tj
T * (solely to reimburse the PROVIDER
for) Tj
19.6667 74.6666 TD(its preparation and distribution costs.If) Tj
0 - 1.1111 TD(a fee is requested, the amount will be) Tj
T * (indicated here: ) Tj / T - 1 1 Tf
7.1568 0 TD(lllll) Tj / F2 1 Tf - 6.1568 - 1.2222 TD(The PROVIDER, RECIPIENT and) Tj - 1 - 1.1111 TD(RECIPIENT SCIENTIST must sign both) Tj
T * (copies of this letter and
return one) Tj
T * (signed copy to the PROVIDER.The) Tj
T * (PROVIDER will then send the) Tj
T * (MATERIAL.) Tj
0 - 1.6667 TD(Provider Information and Authorized) Tj
0 - 1.1111 TD(Signature) Tj
8 0 0 8 399 605 Tm - 0.003 Tw(Provider Scientist: ) Tj / T - 1 1 Tf
9.0039 0 TD(llllllllllll) Tj / F2 1 Tf - 9.0039 - 1.125 TD(Provider Organization: ) Tj / T - 1 1 Tf
11.0048 0 TD(llllllllll) Tj / F2 1 Tf - 11.0048 - 1.125 TD(Address: ) Tj / T - 1 1 Tf
5.0024 0 TD(llllllllllllllll) Tj / F2 1 Tf - 5.0024 - 1.125 TD(Name of Authorized Official: ) Tj / T - 1 1 Tf
14.0103 0 TD(lllllll) Tj / F2 1 Tf - 14.0103 - 1.125 TD(Title of Authorized Official: ) Tj / T - 1 1 Tf
14.0093 0 TD(lllllll) Tj / F3 1 Tf - 14.0093 - 1.125 TD(Certification of Authorized Official: ) Tj / F2 1 Tf
16.6217 0 TD(This) Tj - 16.6217 - 1.125 TD(Simple Letter Agreement) Tj / T - 1 1 Tf
11.7693 0 TD(ll) Tj / F2 1 Tf
2.303 0 TD(has) Tj / T - 1 1 Tf
1.8305 0 TD(ll) Tj / F2 1 Tf
2.303 0 TD(has) Tj - 18.2058 - 1.125 TD(not[check one] been modified.If modified, ) Tj
T * (the modification are attached.) Tj / T - 1 1 Tf
0.0025 - 1.125 TD(lllllllllllllllllllll) Tj / F2 1 Tf - 0.0025 - 1.125 TD(\ (Signature of Authorized Official\)\ (Date\)) Tj
0 - 1.5 TD(Recipient Information and Authorized) Tj
0 - 1.125 TD(Signature) Tj
0 - 1.5 TD(Recipient Scientist: ) Tj / T - 1 1 Tf
10.0044 0 TD(lllllllllll) Tj / F2 1 Tf - 10.0044 - 1.125 TD(Recipient Organization: ) Tj / T - 1 1 Tf
12.0028 0 TD(lllllllll) Tj / F2 1 Tf - 12.0028 - 1.125 TD(Address: ) Tj / T - 1 1 Tf
5.0024 0 TD(llllllllllllllll) Tj / F2 1 Tf - 5.0024 - 1.125 TD(Name of Authorized Official: ) Tj / T - 1 1 Tf
15.0103 0 TD(llllll) Tj / F2 1 Tf - 15.0103 - 1.125 TD(Title of Authorized Official: ) Tj / T - 1 1 Tf
14.0093 0 TD(lllllll) Tj / F2 1 Tf - 14.0093 - 1.125 TD(Signature of Authorized Official: ) Tj / T - 1 1 Tf
16.0088 0 TD(lllll) Tj / F2 1 Tf - 16.0088 - 1.125 TD(Date: ) Tj / T - 1 1 Tf
3.003 0 TD(llllllllllllllllll) Tj / F2 1 Tf - 3.003 - 1.125 TD(Certification of Recipient Scientist: I have) Tj
T * (read and understood the conditions outlined) Tj
T * ( in this Agreement and I agree to abide by) Tj
T * (them in the receipt and use of the) Tj
T * (MATERIAL.) Tj / T - 1 1 Tf
0.0025 - 1.125 TD(lllllllllllllllllllll) Tj / F2 1 Tf - 0.0025 - 1.125 TD(\ (Recipient Scientist\)\ (Date\)) Tj / F3 1 Tf
9 0 0 9 399 350 Tm - 0.004 Tw(Ensuring Consistent Obligations) Tj / F2 1 Tf
1 - 1.6667 TD(Recipients must ensure that) Tj - 1 - 1.1111 TD(obligations to other sources of funding) Tj
T * (of projects in which NIH funds are used) Tj
T * (are consistent with the Bayh - Dole Act) Tj
T * (and NIH funding requirements.Unique) Tj
T * (research resources generated under such) Tj
T * (projects are expected to be made) Tj
T * (available to the research community.) Tj
T * (Recipients are encouraged to share these) Tj
T * (Guidelines with potential co - sponsors.) Tj
T * (Any agreements covering projects in ) Tj
T * (which NIH funds will be used along) Tj
T * (with other funds are expected to contain) Tj
T * (language to address the issue of) Tj
T * (dissemination of unique research) Tj
T * (resources.Examples of possible) Tj
T * (language follow.The paragraphs are) Tj
T * (presented in a``mix and match ''
format: ) Tj
8 0 0 8 407 152 Tm - 0.003 Tw(``The project covered by this agreement is) Tj - 1 - 1.125 TD(supported with funding from the National) Tj
T * (Institutes of Health.Provider agrees that) Tj
T * (upon publication, unpatented unique) Tj
T * (research resources arising out of this project) Tj
T * (may be freely distributed.'') Tj
1 - 1.125 TD(``In the event an invention is primarily) Tj - 1 - 1.125 TD(useful as a research tool, any option granted) Tj
T * (shall either be limited to a non - exclusive) Tj
T * (license or the terms of any resulting) Tj
T * (exclusive license shall include provisions) Tj
T * (that ensure that the research tool will be) Tj / F - 5 1 Tf
6.5 0 0 6.5 60 20 Tm
1 g
0 Tw[(VerDate 10 - DEC - 99) - 1077(10: 32 Dec 22,
1999) - 1077(Jkt 190000) - 1077(PO 00000) - 1077(Frm 00032) - 1077(Fmt 4703) - 1077(Sfmt 4703) - 1077(E: \\FR\\FM\\A23DE3.097) - 1077(pfrm07) - 1077(PsN: 23DEN1)] TJ
ET

// peepdf comment: Javascript code located in object 20 (version 1)

0 G
0 J 0 j 2.2 w 10 M[] 0 d / GS1 gs
1 i
45 744 m
567 744 l
S
0.3 w
45 740 m
567 740 l
S
BT / F1 1 Tf
11 0 0 11 536.42 750 Tm
0 g
0 Tc(72095) Tj
9.8 0 0 10 130.2 750 Tm
0.227 Tw(Federal Register) Tj / F2 1 Tf
8.0007 0 TD[(/)-165(Vol. 64, No. 246)-165(/) - 165(Thursday, December 23, 1999) - 165(/)-165(Notices)]TJ
8 0 0 8 45 726 Tm
-0.003 Tw
(available to the academic research)Tj
0 -1.1 TD
(community on reasonable terms.'')Tj
1 -1.1 TD
(``Provider agrees that Recipient shall have)Tj
-1 -1.1 TD
(the right to make any materials and)Tj
T*
(inventions developed by Recipient in the)Tj
T*
(course of the collaboration \(including)Tj
T*
(materials and inventions developed jointly)Tj
T*
(with Provider, but not including any)Tj
T*
(Provider materials \(or parts thereof\) or)Tj
T*
(Provider sole inventions available to other)Tj
T*
(scientists at not-for-profit organizations for)Tj
T*
(use in research, subject to Provider's)Tj
T*
(independent intellectual property rights.'')Tj
1 -1.1 TD
(``Subject to Recipient's obligations to the)Tj
-1 -1.1 TD
(U.S. government, including 37 CFR Part 401,)Tj
T*
(the NIH Grants Policy Statement, and the)Tj
T*
(NIH Guidelines for Obtaining and)Tj
T*
(Disseminating Biomedical Research)Tj
T*
(Resources, Recipient grants to Sponsor the)Tj
T*
[(following rights: *)-555(*)-555(*'')]TJ
/F3
1 Tf
9 0 0 9 45 544 Tm - 0.004 Tw(Limiting Exclusive Licenses to) Tj
T * (Appropriate Field of Use) Tj / F2 1 Tf
1 - 1.4667 TD(Exclusive licenses
for research tools) Tj - 1 - 1.1 TD(\ (where no further research and) Tj
T * (development is needed to realize the) Tj
T * (invention 's usefulness as a tool\) should)Tj
T*
(generally be avoided except in cases)Tj
T*
(where the licensee undertakes to make)Tj
T*
(the research tool widely available to)Tj
T*
(researchers through unrestricted sale, or)Tj
T*
(the licensor retains rights to make the)Tj
T*
(research tool widely available. When an)Tj
T*
(exclusive license is necessary to)Tj
T*
(promote investment in commercial)Tj
T*
(applications of a subject invention that)Tj
T*
(is also a research tool, the Recipient)Tj
T*
(should ordinarily limit the exclusive)Tj
T*
(license to the commercial field of use,)Tj
T*
(retaining rights regarding use and)Tj
T*
(distribution as a research tool. Examples)Tj
0 -1.1111 TD
(of possible language include:)Tj
8 0 0 8 53 329.8 Tm
-0.003 Tw
(``Research License'' means a)Tj
-1 -1.1 TD
(nontransferable, nonexclusive license to)Tj
T*
(make and to use the Licensed Products or)Tj
T*
(Licensed Processes as defined by the)Tj
T*
(Licensed Patent Rights for purposes of)Tj
T*
(research and not for purposes of commercial)Tj
T*
(manufacture, distribution, or provision of)Tj
T*
(services, or in lieu of purchase, or for)Tj
T*
(developing a directly related secondary)Tj
T*
(product that can be sold. Licensor reserves)Tj
T*
(the right to grant such nonexclusive Research)Tj
T*
(Licenses directly or to require Licenses on)Tj
T*
(reasonable terms. The purpose of this)Tj
T*
(Research License is to encourage basic)Tj
T*
(research, whether conducted at an academic)Tj
T*
(or corporate facility. In order to safeguard the)Tj
T*
(Licensed Patent Rights, however, Licensor)Tj
T*
(shall consult with Licensee before granting to)Tj
T*
(commercial entities a Research License or)Tj
T*
(providing to them research samples of the)Tj
T*
(materials.'')Tj
1 -1.6 TD
(``Licensor reserves the right to provide the)Tj
-1 -1.1 TD
(Biological Materials and to grant licenses)Tj
T*
(under Patent Rights to not-for-profit and)Tj
T*
(governmental institutions for their internal)Tj
T*
(research and scholarly use.'')Tj
1 -1.1 TD
(``Notwithstanding anything to the contrary)Tj
-1 -1.1 TD
(in this agreement, Licensor shall retain a)Tj
T*
(paid-up, nonexclusive, irrevocable license to)Tj
T*
(practice, and to sublicense other not-for-)Tj
T*
(profit research organizations to practice, the)Tj
T*
(Patent Rights for internal research use.'')Tj
23.125 84.125 TD
(``The grant of rights provided herein is)Tj
-1 -1.1 TD
(subject to the rights of the United States)Tj
T*
(government pursuant to the Bayh-Dole Act)Tj
0 -1.1125 TD
(and is limited by the right of the Licensor to)Tj
T*
(use Patent Rights for its own research and)Tj
T*
(educational purposes and to freely distribute)Tj
T*
(Materials to not-for-profit entities for internal)Tj
T*
(research purposes.'')Tj
1 -1.1125 TD
(``Licensor reserves the right to supply any)Tj
-1 -1.1125 TD
(or all of the Biological materials to academic)Tj
T*
(research scientists, subject to limitation of)Tj
T*
(use by such scientists for research purposes)Tj
T*
(and restriction from further distribution.'')Tj
1 -1.1125 TD
(``Licensor reserves the right to practice)Tj
-1 -1.1125 TD
(under the Patent Rights and to use and)Tj
T*
(distribute to third parties the Tangible)Tj
T*
(Property for Licensor'
s own internal research) Tj
T * (purposes.'') Tj / F1 1 Tf
9 0 0 9 222 560 Tm - 0.004 Tw(Guidelines
for Acquiring Research) Tj
0 - 1.1111 TD(Resources
for Use in NIH - Funded) Tj
T * (Research) Tj / F3 1 Tf
0 - 1.6556 TD(Prompt Publication) Tj / F2 1 Tf
1 - 1.4667 TD(Agreements to acquire materials
for) Tj - 1 - 1.1111 TD(use in NIH - funded research are) Tj
T * (expected to address the timely) Tj
T * (dissemination of research results.) Tj
T * (Recipients should not agree to) Tj
T * (significant publication delays, any) Tj
T * (interference with the full disclosure of) Tj
T * (research findings, or any undue) Tj
T * (influence on the objective reporting of) Tj
T * (research results.A delay of 30\26160 days) Tj
T * (to allow
for patent filing or review
for) Tj
T * (confidential proprietary information is) Tj
T * (generally viewed as reasonable.) Tj / F3 1 Tf
0 - 1.6556 TD(Definition of Materials) Tj / F2 1 Tf
1 - 1.4667 TD(Under the Bayh - Dole Act and its) Tj - 1 - 1.1111 TD(implementing regulations, agreements) Tj
T * (to acquire materials
for use in NIH - ) Tj
T * (funded projects cannot require that title) Tj
T * (to resulting inventions be assigned to) Tj
T * (the provider.For this reason, definitions) Tj
T * (of``materials ''
that include all) Tj
T * (derivatives or modifications are) Tj
T * (unacceptable.Other unacceptable) Tj
T * (variations include definitions of) Tj
T * (``materials ''
that include any) Tj
T * (improvements, or any other materials) Tj
T * (that could not have been made without) Tj
T * (the provided material.Conversely, it is) Tj
T * (important
for providers of materials to) Tj
T * (be aware that a Recipient does not gain) Tj
T * (any ownership or interest in a) Tj
T * (provider 's material by virtue of the)Tj
T*
(Recipient using the material in an NIH-)Tj
T*
(funded activity. Examples of acceptable)Tj
T*
(definitions for ``materials'' include:)Tj
8 0 0 8 230 150.9 Tm
-0.003 Tw
[(``)-165(`Materials'
means the materials provided)] TJ - 1 - 1.1125 TD(as specified in this document.'') Tj
1 - 1.1125 TD[(``) - 165(`Materials ' means the materials provided)]TJ
-1 -1.1125 TD
(as specified in this document. Materials may)Tj
T*
(also include Unmodified Derivatives of the)Tj
T*
(materials provided, defined as substances)Tj
T*
(created by the Recipient which constitute an)Tj
T*
(unmodified functional subunit or product)Tj
T*
(expressed by the original material, such as)Tj
T*
(subclones of unmodified cell lines, purified)Tj
T*
(or fractionated subsets of the original)Tj
T*
(materials, proteins expressed by DNA/RNA)Tj
22.125 84.125 TD
(supplied by the Provider, or monoclonal)Tj
0 -1.1375 TD
(antibodies secreted by a hybridoma cell)Tj
T*
(line.'')Tj
1 -1.1375 TD
[(``)-165(`Materials'
means the materials provided)] TJ - 1 - 1.1375 TD(as specified in this document.Materials may) Tj
T * (also include Progeny and Unmodified) Tj
T * (Derivatives of the materials provided.) Tj
T * (Progeny is an unmodified descendant from) Tj
T * (the original material, such as virus from) Tj
0 - 1.125 TD(virus, cell from cell, or organism from) Tj
T * (organism.Unmodified Derivatives are) Tj
T * (substances created by the Recipient which) Tj
T * (constitute an unmodified functional subunit) Tj
T * (or product expressed by the original material, ) Tj
T * (such as subclones of unmodified cell lines, ) Tj
T * (purified or fractionated subsets of the) Tj
T * (original material, proteins expressed by) Tj
T * (DNA / RNA supplied by the Provider, or) Tj
T * (monoclonal antibodies secreted by a) Tj
T * (hybridoma cell line.'') Tj
1 - 1.125 TD[(``) - 165(`Materials ' means the materials being)]TJ
-1 -1.125 TD
(transferred as specified in this document.)Tj
T*
(Materials shall not include: \(a\) Modifications,)Tj
T*
(or \(b\) other substances created by the)Tj
T*
(recipient through the use of the Material)Tj
T*
(which are not Modifications, Progeny, or)Tj
T*
(Unmodified Derivatives. Progeny is an)Tj
T*
(unmodified descendant from the Material,)Tj
T*
(such as virus from virus, cell from cell, or)Tj
T*
(organism from organism. Unmodified)Tj
T*
(Derivatives are substances created by the)Tj
T*
(Recipient which constitute an unmodified)Tj
T*
(functional subunit or product expressed by)Tj
T*
(the original Material, such as subclones of)Tj
T*
(unmodified cell lines, purified or)Tj
T*
(fractionated subsets of the original Material,)Tj
T*
(proteins expressed by DNA/RNA supplied by)Tj
T*
(the Provider, or monoclonal antibodies)Tj
T*
(secreted by a hybridoma cell line.'' [Source:)Tj
T*
(Uniform Biological Materials Transfer)Tj
T*
(Agreement; terms defined therein])Tj
/F3 1 Tf
9 0 0 9 399 350.2 Tm
-0.004 Tw
(Ensuring Consistent Obligations)Tj
/F2 1 Tf
1 -1.9111 TD
(Recipients are expected to avoid)Tj
-1 -1.1111 TD
(signing agreements to acquire research)Tj
T*
(tools that are likely to restrict)Tj
T*
(Recipients'
ability to promote broad) Tj
T * (dissemination of additional tools that) Tj
T * (may arise from the research.This might) Tj
T * (occur when an agreement gives a) Tj
T * (provider an exclusive license option to) Tj
T * (any new intellectual property arising) Tj
T * (out of the project.A new transgenic) Tj
T * (mouse developed during the project) Tj
T * (could fall under this license option and) Tj
T * (become unavailable to third party) Tj
T * (scientists as a result.Examples of) Tj
T * (agreements to examine include material) Tj
T * (transfer agreements\ (MTAs\), ) Tj
T * (memoranda of understanding\ (MOU\), ) Tj
T * (research or collaboration agreements, ) Tj
T * (and sponsored research agreements.) Tj
T * (Recipients should consider adopting) Tj
T * (standard language to place in such) Tj
T * (agreements to address this issue.The) Tj
T * (following are examples of possible) Tj
T * (language to include in MTAs, sponsored) Tj
T * (research agreements, and other) Tj
T * (agreements that either acquire materials) Tj
T * (from or co - mingle funds with non - ) Tj
T * (government sources.The paragraphs are) Tj
T * (presented in a``mix and match ''
format: ) Tj / F - 5 1 Tf
6.5 0 0 6.5 60 20 Tm
1 g
0 Tw[(VerDate 10 - DEC - 99) - 1077(10: 32 Dec 22,
1999) - 1077(Jkt 190000) - 1077(PO 00000) - 1077(Frm 00033) - 1077(Fmt 4703) - 1077(Sfmt 4703) - 1077(E: \\FR\\FM\\A23DE3.099) - 1077(pfrm07) - 1077(PsN: 23DEN1)] TJ
ET

// peepdf comment: Javascript code located in object 23 (version 1)

0 G
0 J 0 j 2.2 w 10 M[] 0 d / GS1 gs
1 i
45 744 m
567 744 l
S
0.3 w
45 740 m
567 740 l
S
BT / F1 1 Tf
11 0 0 11 45 750 Tm
0 g
0 Tc(72096) Tj
9.8 0 0 10 130.2 750 Tm
0.227 Tw(Federal Register) Tj / F2 1 Tf
8.0007 0 TD[(/)-165(Vol. 64, No. 246)-165(/) - 165(Thursday, December 23, 1999) - 165(/)-165(Notices)]TJ
8 0 0 8 53 726 Tm
-0.003 Tw
(``The project covered by this agreement is)Tj
-1 -1.1 TD
(supported with funding from the National)Tj
T*
(Institutes of Health. Provider agrees that after)Tj
0 -1.1125 TD
(publication, unpatented unique research)Tj
T*
(resources arising out of this project may be)Tj
T*
(freely distributed.'')Tj
1 -1.1125 TD
(``In the event an invention is primarily)Tj
-1 -1.1125 TD
(useful as a research tool, any option granted)Tj
T*
(shall either be limited to a non-exclusive)Tj
T*
(license or the terms of any resulting)Tj
T*
(exclusive license shall include provisions)Tj
T*
(which insure that the research tool will be)Tj
T*
(available to the academic research)Tj
T*
(community on reasonable terms.'')Tj
1 -1.1125 TD
(``Provider agrees that Recipient shall have)Tj
-1 -1.1125 TD
(the right to make any materials and)Tj
T*
(inventions developed by Recipient in the)Tj
T*
(course of the collaboration \(including)Tj
T*
(materials and inventions developed jointly)Tj
T*
(with Provider, but not including any)Tj
T*
(Provider materials \(or parts thereof\) or)Tj
T*
(Provider sole inventions available to other)Tj
T*
(scientists at not-for-profit organizations for)Tj
T*
(use in research, subject to Provider's)Tj
T*
(independent intellectual property rights.'')Tj
1 -1.1125 TD
(``Subject to Recipient's obligations to the)Tj
-1 -1.1125 TD
(U.S. government, including 37 CFR Part 401,)Tj
T*
(the NIH Grants Policy Statement, and the)Tj
T*
(NIH Guidelines for Obtaining and)Tj
T*
(Disseminating Biomedical Research)Tj
T*
(Resources, Recipient grants to Sponsor the)Tj
T*
[(following rights: *)-555(*)-555(*'')]TJ
/F3
1 Tf
9 0 0 9 45 435.4 Tm - 0.004 Tw(Grantbacks and Option Rights) Tj / F - 7 1 Tf
1 - 1.4667 TD
0 Tw(\267) Tj / F2 1 Tf
1.0155 0 TD - 0.004 Tw(Agreements to acquire materials) Tj - 2.0155 - 1.1111 TD(from
for -profit entities
for use in NIH - ) Tj
T * (funded research may provide a grant) Tj
T * (back of non - exclusive, royalty - free) Tj
T * (rights to the provider to use) Tj
T * (improvements and new uses of the) Tj
T * (material that,
if patented, would) Tj
T * (infringe any patent claims held by the) Tj
T * (provider.They may also provide an) Tj
T * (option
for an exclusive or non - exclusive) Tj
T * (commercialization license to new) Tj
T * (inventions arising directly from use of) Tj
T * (the material.These should be limited to) Tj
T * (circumstances where the material) Tj
T * (sought to be acquired is unique, such as) Tj
T * (a patented proprietary material, and not) Tj
T * (reasonably available from any other) Tj
T * (source.A non - exclusive``grant - back '') Tj
T * (might be used,
for example, to protect) Tj
T * (a
for -profit entity that provides a) Tj
T * (proprietary compound from being) Tj
T * (blocked from using new uses or) Tj
T * (improvements of that compound) Tj
T * (discovered during the NIH - funded) Tj
T * (project.In providing license options, ) Tj
T * (Recipients must ensure that licenses) Tj
T * (granted to providers under such options) Tj
T * (are consistent with Bayh - Dole) Tj
T * (requirements, including the preference) Tj
T * (
for U.S.industry requirements and) Tj
T * (reservation of government rights under) Tj
T * (47 CFR part 401.) Tj / F - 7 1 Tf
1 - 1.0222 TD
0 Tw(\267) Tj / F2 1 Tf
1.0155 0 TD - 0.004 Tw(In determining the scope of license) Tj - 2.0155 - 1.1111 TD(or option rights that are granted in ) Tj
T * (advance to a provider of materials, ) Tj
T * (Recipient should balance the relative) Tj
T * (value of the provider 's contributions)Tj
T*
(against the value of the rights granted,)Tj
19.6667 74.6666 TD
(cost of the research, and importance of)Tj
0 -1.1111 TD
(the research results. The rights granted)Tj
T*
(to providers should be limited to)Tj
T*
(inventions that have been made directly)Tj
T*
(through the use of the materials)Tj
T*
(provided. In addition, Recipients should)Tj
T*
(reserve the right to negotiate license)Tj
T*
(terms that will ensure: \(1\) continuing)Tj
T*
(availability to the research community if)Tj
T*
(the new invention is a unique research)Tj
T*
(resource; \(2\) that the provider has the)Tj
T*
(technical and financial capability and)Tj
T*
(commitment to bring all potential)Tj
T*
(applications to the marketplace in a)Tj
T*
(timely manner; and \(3\) that if an)Tj
T*
(exclusive license is granted, the)Tj
T*
(provider will provide a commercial)Tj
T*
(development plan and agree to)Tj
T*
(benchmarks and milestones for any)Tj
T*
(fields of use granted.)Tj
/F-7 1 Tf
1 -1.0222 TD
0 Tw
(\267)Tj
/F2 1 Tf
1.0155 0 TD
-0.004 Tw
(It is expected that agreements to)Tj
-2.0155 -1.1111 TD
(acquire NIH-funded materials from not-)Tj
T*
(for-profit entities for use in NIH-funded)Tj
T*
(research will not include)Tj
T*
(commercialization option rights, royalty)Tj
T*
(reach-through, or product reach-through)Tj
T*
(rights back to the provider. Such)Tj
T*
(materials should be acquired under the)Tj
T*
(Simple Letter Agreement or UBMTA, or,)Tj
T*
(if the materials are patented,a simple)Tj
T*
(license agreement that does not request)Tj
T*
(reach-through to either future products)Tj
T*
(or royalties. If the providing not-for-)Tj
T*
(profit organization is constrained in)Tj
T*
(sharing the material due to a pre-)Tj
T*
(existing sponsored research agreement)Tj
T*
(or license, NIH expects that not-for-)Tj
T*
(profit provider to negotiate a suitable)Tj
T*
(resolution with the private research)Tj
T*
(sponsor or licensee. The co-mingling of)Tj
T*
(NIH and sponsored research funds is)Tj
T*
(allowed, however, Recipient is)Tj
T*
(responsible for ensuring that conditions)Tj
T*
(on the use of the sponsored funds do)Tj
T*
(not interfere with the open)Tj
T*
(dissemination of research tools.)Tj
8 0 0 8 222 262.8 Tm
-0.003 Tw
([FR Doc. 99\26133292 Filed12\26122\26199; 8:45 am])Tj
/F-6 1 Tf
6 0 0 6 222 251.8 Tm
0.163 Tw
(BILLING CODE 4140\26101\261M)Tj
ET
222 241.64 m
390 241.64 l
S
BT
9 0 0 9 222 223.5 Tm
-0.004 Tw
(DEPARTMENT OF HEALTH AND)Tj
T*
(HUMAN SERVICES)Tj
0 -2 TD
0.051 Tw
(Substance Abuse and Mental Health)Tj
0 -1.1111 TD
(Services Administration)Tj
0 -2 TD
-0.004 Tw
(Center for Substance Abuse)Tj
0 -1.1111 TD
(Prevention; Notice of Meeting)Tj
/F2 1 Tf
1 -1.6889 TD
(Pursuant to Public Law 92\261463,)Tj
-1 -1.1111 TD
(notice is hereby given of the meeting of)Tj
T*
(the Center for Substance Abuse)Tj
T*
(Prevention \(CSAP\) National Advisory)Tj
T*
(Council in January 2000.)Tj
1 -1.0333 TD
(The meeting will be open. The agenda)Tj
-1 -1.1111 TD
(will include presentations and updates)Tj
T*
(on CSAP'
s programs, the SAMHSA) Tj
T * (Administrator 's Report, a CSAP budget)Tj
T*
(update, and discussions of)Tj
19.6667 74.6666 TD
(administrative matters and)Tj
0 -1.1111 TD
(announcements. If anyone needs special)Tj
T*
(accommodations for persons with)Tj
T*
(disabilities, please notify the contact)Tj
T*
(listed below.)Tj
1 -1.1111 TD
(A summary of this meeting, a roster)Tj
-1 -1.1111 TD
(of committee members, and substantive)Tj
T*
(program information may be obtained)Tj
T*
(from the contact listed below.)Tj
/F3 1 Tf
8 0 0 8 407 632 Tm
-0.003 Tw
(Committee Name: )Tj
/F2 1 Tf
8.5339 0 TD
(Center for Substance)Tj
-9.5339 -1.125 TD
(Abuse Prevention National Advisory Council)Tj
/F3 1 Tf
1 -1.125 TD
(Meeting Dates: )Tj
/F2 1 Tf
7.0319 0 TD
(January 10, 2000, 9 a.m.\2615)Tj
-8.0319 -1.125 TD
(p.m. \(Open\))Tj
/F3 1 Tf
1 -1.125 TD
(Place: )Tj
/F2 1 Tf
3.0355 0 TD
(Bethesda Marriott Hotel, 5151 Pooks)Tj
-4.0355 -1.125 TD
(Hill Road, Bethesda, Maryland 20841.)Tj
/F3 1 Tf
1 -1.125 TD
(Contact: )Tj
/F2 1 Tf
4.1094 0 TD
(Yuth Nimit, Ph.D., 5600 Fishers)Tj
-5.1094 -1.125 TD
(Lane, Rockwall II Building, Suite 901,)Tj
T*
(Rockville, Maryland 20857, Telephone: \(301\))Tj
T*
(443\2618455.)Tj
1 -1.375 TD
(Dated: December 17, 1999.)Tj
/F1 1 Tf
-1 -1.375 TD
(Sandra Stephens,)Tj
/F3 1 Tf
T*
-0.058 Tw
(Acting Committee Management Officer,)Tj
0 -1.125 TD
(Substance Abuse and Mental Health Services)Tj
T*
(Administration.)Tj
/F2 1 Tf
0 -1.375 TD
-0.003 Tw
([FR Doc. 99\26133306 Filed 12\26122\26199; 8:45 am])Tj
/F-6 1 Tf
6 0 0 6 399 478 Tm
0.163 Tw
(BILLING CODE 4162\26120\261P)Tj
ET
1.2 w 
399 467.8 m
567 467.8 l
S
0.3 w 
399 464.04 m
567 464.04 l
S
BT
9 0 0 9 399 445.9 Tm
-0.004 Tw
(DEPARTMENT OF HOUSING AND)Tj
0 -1.1111 TD
(URBAN DEVELOPMENT)Tj
8 0 0 8 399 420.3 Tm
-0.003 Tw
([Docket No. FR\2614432\261N\26151])Tj
9 0 0 9 399 402.3 Tm
-0.004 Tw
(Federal Property Suitable as Facilities)Tj
T*
(to Assist the Homeless)Tj
7.2 0 0 7.441 399 376.3 Tm
(AGENCY)Tj
9 0 0 9 429.8 376.3 Tm
(: )Tj
/F2 1 Tf
0.6065 0 TD
(Office of the Assistant)Tj
-4.0288 -1.1111 TD
(Secretary for Community Planning and)Tj
T*
(Development, HUD.)Tj
/F-6 1 Tf
7.2 0 0 7.441 399 344.3 Tm
(ACTION)Tj
9 0 0 9 426.596 344.3 Tm
(: )Tj
/F2 1 Tf
0.6065 0 TD
(Notice.)Tj
ET
399 339.14 m
567 339.14 l
S
BT
/F-6 1 Tf
7.2 0 0 7.441 399 327 Tm
(SUMMARY)Tj
9 0 0 9 436.194 327 Tm
(: )Tj
/F2 1 Tf
0.6065 0 TD
(This Notice identifies)Tj
-4.7392 -1.1111 TD
(unutilized, underutilized, excess, and)Tj
T*
(surplus Federal property reviewed by)Tj
T*
(HUD for suitability for possible use to)Tj
T*
(assist the homeless.)Tj
/F-6 1 Tf
7.2 0 0 7.441 399 275 Tm
[(FOR)-342(FURTHER)-342(INFORMATION)-342(CONTACT)]TJ
9 0 0 9 541.958 275 Tm
0 Tw
(:)Tj
/F2 1 Tf
-15.8842 -1.1111 TD
-0.004 Tw
(Clifford Taffet, room 7266, Department)Tj
T*
(of Housing and Urban Development,)Tj
T*
(451 Seventh Street SW, Washington, DC)Tj
T*
(20410; telephone \(202\) 708\2611234; TTY)Tj
T*
(number for the hearing- and speech-)Tj
T*
(impaired \(202\) 708\2612565 \(these)Tj
T*
(telephone numbers are not toll-free\), or)Tj
T*
(call the toll-free Title V information line)Tj
T*
(at 1\261800\261927\2617588.)Tj
/F-6 1 Tf
7.2 0 0 7.441 399 173 Tm
[(SUPPLEMENTARY)-342(INFORMATION)]TJ
9 0 0 9 516.655 173 Tm
(: )Tj
/F2 1 Tf
0.6065 0 TD
(In)Tj
-13.6793 -1.1111 TD
(accordance with 24 CFR Part 581 and)Tj
T*
(section 501 of the Stewart B. McKinney)Tj
T*
(Homeless Assistance Act \(42 U.S.C.)Tj
T*
(11411\), as amended, HUD is publishing)Tj
T*
(this Notice to identify Federal buildings)Tj
T*
(and other real property that HUD has)Tj
T*
(reviewed for suitability for use to assist)Tj
T*
(the homeless. The properties were)Tj
T*
(reviewed using information provided to)Tj
T*
(HUD by Federal landholding agencies)Tj
T*
(regarding unutilized and underutilized)Tj
T*
(buildings and real property controlled)Tj
/F-5 1 Tf
6.5 0 0 6.5 60 20 Tm
1 g
0 Tw
[(VerDate 10-DEC-99)-1077(10:32 Dec 22, 1999)-1077(Jkt 190000)-1077(PO 00000)-1077(Frm 00034)-1077(Fmt 4703)-1077(Sfmt 4703)-1077(E:\\FR\\FM\\A23DE3.101)-1077(pfrm07)-1077(PsN: 23DEN1)]TJ
ET

